Country Club Trust Company n.a. grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 4.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 19,105 shares of the healthcare product maker’s stock after buying an additional 786 shares during the period. Country Club Trust Company n.a.’s holdings in Abbott Laboratories were worth $1,382,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. NewSquare Capital LLC boosted its position in Abbott Laboratories by 14.2% during the 4th quarter. NewSquare Capital LLC now owns 1,290 shares of the healthcare product maker’s stock worth $93,000 after purchasing an additional 160 shares during the period. Jolley Asset Management LLC boosted its position in Abbott Laboratories by 0.5% during the 4th quarter. Jolley Asset Management LLC now owns 32,721 shares of the healthcare product maker’s stock worth $2,367,000 after purchasing an additional 166 shares during the period. Lourd Capital LLC boosted its position in Abbott Laboratories by 1.8% during the 4th quarter. Lourd Capital LLC now owns 10,407 shares of the healthcare product maker’s stock worth $753,000 after purchasing an additional 181 shares during the period. Iron Financial LLC boosted its position in Abbott Laboratories by 5.0% during the 4th quarter. Iron Financial LLC now owns 3,865 shares of the healthcare product maker’s stock worth $280,000 after purchasing an additional 184 shares during the period. Finally, Independent Investors Inc. boosted its position in Abbott Laboratories by 0.4% during the 4th quarter. Independent Investors Inc. now owns 52,750 shares of the healthcare product maker’s stock worth $3,815,000 after purchasing an additional 200 shares during the period. 74.36% of the stock is owned by institutional investors.
ABT has been the subject of a number of research reports. Goldman Sachs Group raised shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and set a $74.10 price target for the company in a research report on Sunday, December 9th. Gabelli reaffirmed a “buy” rating on shares of Abbott Laboratories in a research report on Wednesday, January 2nd. UBS Group initiated coverage on shares of Abbott Laboratories in a research report on Tuesday, November 27th. They set a “buy” rating and a $83.00 price target for the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $80.00 price target on shares of Abbott Laboratories in a research report on Thursday, October 18th. Finally, Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $80.00 price objective on the stock in a report on Monday, January 28th. One analyst has rated the stock with a sell rating, three have given a hold rating and sixteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $79.48.
Shares of ABT stock opened at $74.38 on Thursday. Abbott Laboratories has a 12 month low of $56.81 and a 12 month high of $75.27. The company has a current ratio of 1.42, a quick ratio of 1.13 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $128.79 billion, a price-to-earnings ratio of 25.83, a PEG ratio of 1.95 and a beta of 1.14.
Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, January 23rd. The healthcare product maker reported $0.81 EPS for the quarter, hitting analysts’ consensus estimates of $0.81. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.82 billion. Abbott Laboratories had a net margin of 7.74% and a return on equity of 16.50%. The firm’s revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.74 EPS. Sell-side analysts forecast that Abbott Laboratories will post 3.2 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, February 15th. Stockholders of record on Tuesday, January 15th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.72%. The ex-dividend date of this dividend is Monday, January 14th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.28. Abbott Laboratories’s dividend payout ratio is 44.44%.
In related news, Director John G. Stratton bought 3,455 shares of the business’s stock in a transaction dated Thursday, January 31st. The shares were acquired at an average price of $72.32 per share, for a total transaction of $249,865.60. Following the purchase, the director now owns 3,558 shares in the company, valued at approximately $257,314.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Chairman Miles D. White sold 142,341 shares of the company’s stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $72.35, for a total transaction of $10,298,371.35. Following the completion of the sale, the chairman now owns 3,459,185 shares in the company, valued at approximately $250,272,034.75. The disclosure for this sale can be found here. Corporate insiders own 0.74% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Macon Daily and is owned by of Macon Daily. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://macondaily.com/2019/02/14/country-club-trust-company-n-a-increases-stake-in-abbott-laboratories-abt.html.
About Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.
Further Reading: What are no-load funds?
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.